Because no current therapy for type 2 diabetes offers disease-modifying capabilities, there is high unmet need for drugs that can effectively control the disease. DRG’s Type 2 Diabetes Unmet Need 2017 focuses on injectable agents: insulins and GLP-1 receptor agonists. In DRG’s view, currently marketed injectables have scope to further move up the treatment algorithm. Therefore, understanding physicians’ perspectives on these products is increasingly important. In this content we reveal which drug attributes drive endocrinologists’ prescribing and explore how current injectables compare across efficacy, safety, and delivery attributes.
Markets covered: United States, United Kingdom, France, Germany
Primary research: Survey of 60 U.S. and 31 European endocrinologists fielded in March 2017.
Key companies: Boehringer Ingelheim, Eli Lilly, Novo Nordisk, Sanofi
Key drugs: Lantus, Basaglar, Toujeo, Tresiba, Trulicity, Victoza